Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Wallace Rivers who wrote (28620)	3/31/1999 12:39:00 PM
From: Cheryl Galt	Read Replies (1) \| Respond to of 32384

Wallace, you don't have to fess up after all, except maybe to dyslexia ... ;-) >> although the Street was looking for "only" (.20) and LGND came in at (.29) << I also look at my monitor without glasses. (Mine are no help with middle distances.) Be alerted... 5s look a lot like 2s. LGND came in at (.59) -- excluding a one-time $15M charge for acquired in-process technology. I was expecting (.40) like last quarter, or (.45), so i was surprised by that five. It's a good thing the Street was expecting low-revenue results, and so the stock price seems not affected this morning. $8.5 support seems to be holding. I'm convinced hype hurts a stock -- and steady, honest information helps build confidence in a company. Regards, Cheryl